Additionally, in vivo, letrozole (ARO inhibitor) improved pembrolizumab efficacy, while in NSCLC patients, ERα was a predictive response factor to pembrolizumab, even stronger than sex and PD-L1 levels (92). This evidence concerns the gene ESR1 and non-small cell lung carcinoma.